Glucocorticoid-induced osteoporosis

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 3, 2001, Pages 140-145

  Cooper, Mark S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; GROWTH FACTOR; RISEDRONIC ACID;

BONE MASS; CELL COUNT; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG MECHANISM; FRACTURE; HORMONE ACTION; HUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; REVIEW; RISK FACTOR;

EID: 0035014992     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200106000-00006     Document Type: Review

References (45)

1. 1 Cushing HW: The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932, 50:137-195.
2. 2 Canalis E: Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes 2000, 7:320-324.
3. 3 van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105-111. This is the most accurate epidemiologic assessment of current oral glucocorticoid usage in the United Kingdom.
4. 4 van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000. This is a cohort study of 500,000 individuals examining dose dependency and time course of fracture risk with oral glucocorticoids. Fracture risk increased rapidly after beginning glucocorticoid treatment, and all levels of glucocorticoid use predisposed to fracture.
5. 5 Wong CA, Walsh U, Smith CJ, et al.: Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000, 355:1399-1403.
6. 6 Canalis E: Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996, 81:3441-3447.
7. 7 Manolagas SC, Anderson DC: Detection of high-affinity glucocorticoid binding in rat bone. J Endocrinol 1978, 76:379-380.
8. 8 Chen TL, Aronow L, Feldman D: Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology 1977, 100:619-628.
9. 9 Abu EO, Horner A, Kusec V, et al.: The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 2000, 85:883-889. This is the first detailed description of GR expression in human bone cells in vivo.
10. 10 Pereira RC, Blanquaert F, Canalis E: Cortisol enhances the expression of mac25/insulin-like growth factor-binding protein-related protein-1 in cultured osteoblasts. Endocrinology 1999, 140:228-232.
11. 11 Pereira RC, Durant D, Canalis E: Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts. Am J Physiol Endocrinol Metab 2000, 279:E570-E576.
12. 12 Grano M, Galimi F, Zambonin G, et al.: Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A 1996, 93:7644-7648.
13. 13 Blanquaert F, Delany AM, Canalis E: Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Endocrinology 1999, 140:1069-1074.
14. 14 Skrtic S, Ohlsson C: Cortisol decreases hepatocyte growth factor levels in human osteoblast-like cells. Calcif Tissue Int 2000, 66:108-112.
15. 15 Blanquaert F, Pereira RC, Canalis E: Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol Metab 2000, 278:E509-E515.
16. 16 McCarthy TL, Ji C, Chen Y, et al.: Time-and dose-related interactions between glucocorticoid and cyclic adenosine 3′,5′-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts. Endocrinology 2000, 141:127-137.
17. 17 Smith E, Redman RA, Logg CR, et al.: Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes. J Biol Chem 2000, 275:19992-20001.
18. 18 Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137. This review of evidence supports the importance of altered bone cell numbers in various bone diseases rather than changes in the function of differentiated bone cells.
19. 19 Weinstein RS, Jilka RL, Parfitt AM, et al.: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282. This is an important paper that characterized a murine model of glucocorticoid-induced osteoporosis and, using this model, presented evidence that increased apoptosis of osteoblasts is an important mechanism in this condition.
20. 20 Weinstein RS, Nicholas RW, Manolagas SC: Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.
21. 21 Silvestrini G, Ballanti P, Patacchioli FR, et al.: Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone 2000, 26:33-42.
22. 22 Suda T, Takahashi N, Udagawa N, et al.: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
23. 23 Hofbauer LC, Gori F, Riggs BL, et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389. This study demonstrates changes in osteoprotegerin and RANKL expression with glucocorticoids that potentially accounts for an early phase of osteoclastic bone resorption with glucocorticoid treatment.
24. 24 Chiodini I, Carnevale V, Torlontano M, et al.: Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998, 83:1863-1867.
25. 25 Dennison E, Hindmarsh P, Fall C, et al.: Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 1999, 84:3058-3063. This is a demonstration that endogenous glucocorticoid levels in normal men are important in determining the rate of bone loss at multiple sites over time.
26. 26 Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996, 17:245-261.
27. 27 Cooper MS, Hewison M, Stewart PM: Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol 1999, 163:159-164.
28. 28 Huizenga NA, Koper JW, De Lange P, et al.: A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998, 83:144-151.
29. 29 Stewart PM, Krozowski ZS: 11β-Hydroxysteroid dehydrogenase. Vitam Horm 1999, 57:249-324.
30. 30 Cooper MS, Walker EA, Biand R, et al.: Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 2000, 27:375-381. This is the first study reporting that osteoblasts in vivo express glucocorticoid-modifying enzymes and can interconvert inactive and active corticosteroids.
31. 31 Sambrook PN: Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000, 15:1645-1649.
32. 32 Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387. This is a randomized controlled trial of the bisphosphonate etidronate in glucocorticoid-induced osteoporosis.
33. 33 Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292-299. This is a randomized controlled trial of the bisphosphonate alendronate in glucocorticoid-induced osteoporosis.
34. 34 Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318. This is the first randomized controlled trial of the bisphosphonate risedronate in glucocorticoid-induced osteoporosis.
35. 36 Reid DM, Hughes RA, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000, 15:1006-1013.
36. 36 Wallach S, Cohen S, Reid DM, et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
37. 37 Compston JE: Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis. Gut 1999, 44:780-781.
38. 38 Lanza FL, Hunt RH, Thomson AB, et al.: Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000, 119:631-638.
39. 39 Chavassieux PM, Arlot ME, Roux JP, et al.: Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000, 15:754-762.
40. 40 Reginster JY, Kuntz D, Verdickt W, et al.: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999, 9:75-81.
41. 41 Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633. This randomized controlled trial of PTH injections in patients with established glucocorticoid-induced osteoporosis demonstrated a substantial anabolic action of PTH at the spine and subsequently the hip.
42. 42 Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
43. 43 Lane NE, Sanchez S, Genant HK, et al.: Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000, 11:434-442.
44. 44 Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
45. 45 Webster JC, Cidlowski JA: Mechanisms of Glucocorticoid-receptor-mediated Repression of Gene Expression. Trends Endocrinol Metab 1999, 10:396-402.